Amylin Pharmaceuticals

Amylin Pharmaceuticals

Type	Private
Industry	Biotechnology
Founded	1987
Headquarters	San Diego, California, United States
Key people	Daniel M. Bradbury[1]
Products	Symlin (pramlintide) Byetta (exenatide)
Revenue	US$758M (FY 2009)[2]
Operating income	US$-173M (FY 2009)[2]
Net income	US$-186M (FY 2009)[2]
Total assets	US$1.73B (FY 2009)[3]
Total equity	US$423M (FY 2009)[3]
Number of employees	1,900
Website	www.amylin.com

Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987. The company is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Currently, Amylin produces three drugs: Symlin (pramlintide acetate), Byetta (exenatide) and Bydureon (exenatide extended-release). On February 4, 2014, the U.S. FDA approved Myalept (metreleptin), an analog of human leptin,^[4] as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy.^[5]

In July 2012, Bristol-Myers Squibb announced it would acquire Amylin Pharmaceuticals for $5.3 billion.^[6]

In December 2013, Amylin was acquired by AstraZeneca.^[7]

References

External links